01—Abstract
Summary
Summary of the 10-Q filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Biogen Inc. reported net income of $388.5 milliona, or $2.66 per diluted share, for the third quarter of 2024, a significant improvement from a net loss of $68.1 million in the same period last year.
This turnaround was driven by a substantial decrease in total costs and expenses, including lower R&D and SG&A expenses, partly due to the phasing out of acquisition-related equity compensation costs recognized in the prior year. Total revenue saw a slight decrease of 2.5% to $2.47 billionb, mainly impacted by a 9.1% decline in Multiple Sclerosis (MS) product revenue due to increased competition, particularly for TYSABRI and TECFIDERA. The company successfully completed the acquisition of HI-Bio for $1.15 billion in July 2024, adding felzartamab to its pipeline for severe immune-mediated diseases.
This strategic move is expected to bolster Biogen's immunology and rare disease portfolios. While overall MS revenue continues to face challenges from generic competition and shifting patient preferences towards higher efficacy therapies, the Rare Disease segment showed strong growth, primarily driven by the initial sales of SKYCLARYS, acquired through the Reata transaction in late 2023. Biogen's financial position remains solid with cash and cash equivalents increasing to $1.7 billionc.
The company generated $2.1 billiond in operating cash flow for the first nine months of the year. Despite ongoing competitive pressures in key therapeutic areas, Biogen's focus on pipeline advancement and strategic acquisitions positions it to navigate the evolving biopharmaceutical landscape. Investors should monitor the performance of newer products like SKYCLARYS and the progress of pipeline assets such as felzartamab, while also considering the continued challenges in the MS segment.
02—Key points
Key Highlights
- Biogen reported a strong Q3 2024 with net income of $388.5 million ($2.66/share), a significant turnaround from a net loss of $68.1 million in Q3 2023.
- Total revenue decreased slightly by 2.5% to $2.47 billion, impacted by a 9.1% decline in Multiple Sclerosis (MS) revenue due to competition.
- Rare Disease revenue increased by 10.0%, driven by $102.3 million in SKYCLARYS sales in Q3 2024.
- The company completed the acquisition of HI-Bio for $1.15 billion in July 2024, strengthening its immunology pipeline with felzartamab.
- Total costs and expenses decreased by 24.6% to $2.01 billion, primarily due to lower R&D and SG&A expenses compared to the prior year's acquisition-related costs.
- Cash and cash equivalents increased to $1.7 billion as of September 30, 2024, with strong operating cash flow generation of $2.1 billion for the first nine months of the year.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 30, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $2.47B$2.53B | −2.5% |
| Cost of Revenue | $638.70M$659.60M | −3.2% |
| Gross Profit | $1.83B$1.87B | −2.3% |
| SG&A Expenses | $588.40M$788.20M | −25.3% |
| Operating Expenses | $2.01B$2.67B | −24.6% |
| Interest Expense | $59.80M$63.80M | −6.3% |
| Net Income | $388.50M-$68.10M | +670.5% |
| EPS (Basic) | $2.67$-0.47 | +668.1% |
| EPS (Diluted) | $2.66$-0.47 | +666.0% |
| Shares Outstanding (Basic) | 145.70M144.80M | +0.6% |
| Shares Outstanding (Diluted) | 146.10M144.80M | +0.9% |
05—Questions
Frequently Asked Questions
What was Biogen's financial performance in Q3 2024 compared to Q3 2023?
Biogen reported a significant improvement in Q3 2024, with a net income of $388.5 million ($2.66 per diluted share), compared to a net loss of $68.1 million ($0.47 per diluted share) in Q3 2023. This was driven by a substantial decrease in total costs and expenses, more than offsetting a slight 2.5% decrease in total revenue to $2.47 billion.
What factors contributed to the decrease in total revenue?
The overall revenue decrease was primarily due to a 9.1% decline in Multiple Sclerosis (MS) product revenue, which fell to $1.05 billion from $1.16 billion year-over-year. This decline is attributed to increased competition, generic entrants for products like TECFIDERA, and a decrease in demand for Interferon-based therapies as patients shift to higher efficacy treatments. Revenue from contract manufacturing, royalty, and other sources also decreased.
What was the impact of the HI-Bio acquisition on Biogen's financials?
Biogen completed the acquisition of HI-Bio for $1.15 billion in July 2024, funded by cash on hand. This acquisition adds felzartamab to Biogen's pipeline, targeting severe immune-mediated diseases. While the acquisition itself did not have a significant impact on revenue in Q3 2024, it represents a strategic investment in future growth areas. The associated equity-based compensation for HI-Bio employees was approximately $42.5 million in R&D and $13.9 million in SG&A for Q3 2024.
How is Biogen managing its expenses, and what drove the decrease in R&D and SG&A?
Total costs and expenses decreased by 24.6% to $2.01 billion in Q3 2024. R&D expenses decreased by 26.3% due to a significant factor being the absence of the large equity-based compensation expense related to the Reata acquisition in the prior year ($197 million). Cost-reduction measures from the 'Fit for Growth' program also contributed. SG&A expenses similarly decreased by 25.3%, largely due to the year-over-year reduction in acquisition-related equity compensation costs (Reata: $196.4 million in prior year).
06—Continue